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Small cell lung cancer (SCLC), is a particularly aggressive form of
lung cancer, it metastasizes widely and early and many patients
have widespread metastases at presentation, precluding curative
surgery (Ihde, 1992). Despite initial sensitivity to radio and
chemotherapy SCLC almost invariably relapses, so that the 2-year
survival remains less than 5% (Smyth et al, 1986). Novel forms of
treatment are therefore urgently required.
SCLC cell proliferation is driven by multiple autocrine and
paracrine growth loops involving calcium-mobilizing neuro-
peptides, including bradykinin, cholecystokinin, galanin, gastrin,
gastrin releasing peptide (GRP), neurotensin and vasopressin
(Moody et al, 1981; Cuttitta et al, 1985; Sethi and Rozengurt,
1991). Interruption of the mitogenic second messenger signals
initiated by these neuropeptides could offer a novel and effective
form of treatment to prevent SCLC cell growth. [D-Arg6, D-Trp7,9,
NmePhe8]-substance P (6–11) (antagonist G) is a novel anti-cancer
agent which is entering phase II clinical trials for the treatment of
SCLC (Langdon et al, 1994; Jonkman-de Vries et al, 1998).
Antagonist G belongs to a family of substance P-related peptides
which inhibit the growth of SCLC cells in vitro and in vivo (Woll
and Rozengurt, 1990; Sethi et al, 1992). Early studies in Swiss 3T3
cells showed that antagonist G and related substance P analogues
inhibit the binding of neuropeptides to their receptors (Woll and
Rozengurt 1988; Mitchell et al, 1995; Seckl et al, 1995), thus
inhibiting neuropeptide stimulated mitogenic signalling (Mitchell
et al, 1995; Seckl et al, 1995; 1996; 1997). However, recently 
it has been shown that in addition to inhibiting neuropeptide
responses, antagonist G, and its analogue antagonist D, also have
important agonist activity, activating c-jun N terminal kinase
(JNK) in a neuropeptide-independent manner (Jarpe et al, 1998a;
MacKinnon et al, 1999). These studies provide the molecular basis
to understanding the mechanisms by which antagonist G inhibits
both basal and neuropeptide-stimulated SCLC growth (Sethi et al,
1992; Langdon et al, 1994).
Apoptosis is an active cell-death programme which is initiated
via specific signal transduction cascades (Kerr et al, 1972;
Kyprianou et al, 1992). Factors affecting the balance between
SCLC cell proliferation and apoptosis will have a profound effect
on tumour growth. The stress-activated protein kinases or c-jun 
N-terminal kinases (JNKs) have been shown to be activated in
response to apoptotic stimuli in several cell types (Verheij et al,
1996; Le-Niculescu, 1999). Previous studies have shown that
expression of a dominant negative JNK1 mutant in SCLC cells
inhibits UV-induced apoptosis, suggesting an essential role of
JNK1 in the induction of apoptosis in SCLC cells (Butterfield 
et al, 1997). Our previous work has shown that antagonist G
activates JNK1 in SCLC cells (MacKinnon et al, 1999).
The role of reactive oxygen species (ROS) in pathways leading
to apoptosis is particularly pertinent in cancers where the oxygen
tension at the centre of tumours may be particularly low (Bush et
al, 1978). Although the exact role of ROS in the induction of apop-
tosis is unclear, it is becoming well established that ROS may be
involved in the relay of early apoptotic signals by acting as
signalling intermediates (Lo and Cruz, 1995). Recent evidence
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doi: 10.1054/ bjoc.2000.1362, available online at http://www.idealibrary.com on suggests that different forms of chemotherapy primarily exert their
cytotoxic effects by inducing apoptosis (Friesen et al, 1999). The
generation of intracellular ROS and/or the depletion of intra-
cellular antioxidants may sensitize tumours to the pro-apoptotic
effects of chemotherapeutic agents (Carmichael et al, 1988).
The aim of this study was to define the molecular mechanisms
underlying these observations and their relevance to the use of
antagonist G in clinical practice. Our results show that antagonist
G induces ROS generation and stimulates lipid peroxidation while
reducing GSH levels. This is cell type-specific and plays an impor-
tant part in the apoptotic effect of antagonist G. In addition we
show that antagonist G sensitizes SCLC cells to chemotherapeutic
agents. These findings have important implications in the future
clinical use and development of antagonist G and in the design of
novel therapeutic agents to treat this aggressive cancer.
MATERIALS AND METHODS
Materials
SCLC cell lines NCI-H69 and NCI-H510 and CHO-K1 cells were
purchased from the American Type Tissue Culture Collection
(Rockville, MD, USA); RPMI-1640, dihydrorhodamine and
etoposide from Sigma (Poole, Dorset, UK); annexin V-FITC 
from Bender Medsystems (UK); antagonist G ([Arg6, D-Trp7,9,
NmePhe8]-substance P (6–11)) was a kind gift from Peptec
(Copenhagen, Denmark). All other reagents were of the purest
grade available.
Cell culture
NCI-H69 and NCI-H510 SCLC cells were cultured in RPMI 1640
medium with 25 mM HEPES supplemented with 10% (v/v) fetal
bovine serum, 50 U ml–1 penicillin, 50 mg ml–1 streptomycin and 
5 mg ml–1 L-glutamine in a humidified atmosphere of 5% CO2/95%
air at 37°C. For experimental purposes, the cells were grown in
SITA medium consisting of RPMI 1640 medium supplemented
with 30 nM selenium, 5 mg ml–1 insulin, 10 mg ml–1 transferrin and
0.25% (w/v) BSA. Cells were quiesced in serum-free RPMI 1640
medium containing 0.25% (w/v) BSA. In anoxic studies, cells were
incubated at 37°C in a MK3 anaerobic incubator with 0% oxygen
(Don Whitely Scientific Ltd, Yorkshire, UK). CHO-K1 cells were
maintained in Dulbecco’s modified Eagles medium (DMEM)
containing 10% (v/v) fetal calf serum, 50 U ml–1 penicillin, 50 mg
ml–1 streptomycin and 5 mg ml–1 L-glutamine.
Measurement of apoptosis
SCLC cells (106 cells ml–1) were incubated in quiescent medium in
the presence or absence of antagonist G or other test agents for 
24 h. CHO-K1 cells were incubated with antagonist G in DMEM
containing 0.1% fetal bovine serum for 24 h.
Morphology
Cells were cytocentrifuged onto glass slides, fixed with methanol,
stained with May–Grünwald–Giemsa stain and examined using 
an Olympus BH-2 microscope, at a magnification of ´ 400.
Apoptotic SCLC cells displayed typical morphological features,
including cell shrinkage and chromatin condensation as previously
described (Tallet et al, 1996).
Annexin V binding
H69 cells and trypsinized CHO-K1 cells were washed in PBS and
incubated with annexin V-FITC (1:250) for 10 min at 4°C then
fixed in 3% paraformaldehyde. The percentage of annexin V
positive cells were determined by flow cytometry using an EPICS
Profile II flow cytometer (Coulter Electronics, Luton, UK).
DNA laddering
DNA ladders from antagonist G-treated cells were prepared as
described (Tallet et al, 1996).
Measurement of intracellular reactive oxygen species
(ROS)
Intracellular ROS were measured by dihydrorhodamine fluores-
cence. H69 SCLC cells and trypsinized CHO-K1 cells were
washed and incubated (106 cells ml–1) with 1 mM dihydrorhod-
amine (DHR) for 5 min at 37°C in phosphate buffered saline
(PBS) prior to the addition of antagonist G or H2O2 for a further 
10 min at 37°C. Fluorescence was measured by flow cytometry
using an EPICS Profile II flow cytometer (Coulter Electronics,
Luton, UK).
Measurement of c-jun-N terminal kinase (JNK)
Quiesced H69 cells were washed twice in PBS (pH 7.4), and incu-
bated for various times with test agents as indicated in the figure
legends. Following immunoprecipitation of JNK1 from whole cell
lysates, kinase activity was carried out as described (Coso et al,
1995; MacKinnon et al, 1999) 1 mg GST-c-jun(79) substrate.
Phosphorylated c-jun was identified from autoradiographs of
Coomasie Blue stained-SDS-PAGE gels, and quantified by optical
densitometry.
Measurement of AP-1 activity
H69 cells were quiesced overnight in serum-free medium, washed
and incubated (107 cells ml–1) with test agents for 30 min at 37°C.
Nuclear extracts were prepared by the method of Staal et al (1990).
The oligonucleotides for AP-1 (Promega) were end-labelled using
T4 polynucleotide kinase and [g32P]-ATP (Promega). Binding
reactions were carried out using 5 mg nuclear extract protein, 0.25
mg ml–1 poly (dI-dC).poly (dI-dC) (Pharmacia Biotech, St.
Albans, UK), in 20 ml binding buffer (Promega). Competition
studies were carried out using a 100-fold excess of either unla-
belled AP-1 oligonucleotide (competitor) or unlabelled NFkb
oligonucleotide (non-competitor). The protein complexes were
resolved on 6% non-denaturing polyacrylamide gels and detected
by autoradiography.
Measurement of lipid peroxidation and cellular
glutathione levels
SCLC cells (107 cells ml–1) in serum-free media were incubated
with antagonist G for 24 h. Lipid peroxides were assayed as
thiobarbituric acid reactive substances (TBARS) as previously
described (Ohkawa et al, 1979). Following precipitation of
proteins with 0.1% (v/v) Triton X-100 and 0.6% (w/v) sulphosali-
cylic acid, total cellular glutathione was measured as described
(Tietze, 1969).
942 AC MacKinnon et al
British Journal of Cancer (2000) 83(7), 941–948 © 2000 Cancer Research CampaignCeramide quantitation
SCLC cells (107 cells ml–1) in SITA medium were treated with test
agents as indicated and the lipids extracted (Bligh et al, 1959) and
dried under vacuum. Ceramide was quantitated using the diacyl-
glycerol (DAG) kinase assay as previously described (Jayadev et
al, 1994).
Chemosensitivity
SCLC cells, 3–5 days post-passage, were washed and resuspended
in SITA medium at a density of 5 ´ 104 cells ml–1 in the presence of
0–100 mg ml–1 etoposide with or without antagonist G. At each
time-point cell number was determined using a Coulter counter
(Coulter Electronics).
RESULTS
Antagonist G-induced apoptosis is redox-sensitive and
caspase-dependent
Antagonist G caused a marked concentration-dependent stimulation
of apoptosis in SCLC cells as judged morphologically. In the SCLC
cell line H69, antagonist G (25 mM) increased basal apoptosis from
10.5 ± 4.2% to 37.1 ± 5.4% (n = 4), with an EC50 of 5.9 ± 0.1 mM 
(n = 4, Figure 1A). Antagonist G also induced apoptosis in the
SCLC cell line H510 with an EC50 value of 15.2 ± 2.7 mM (Figure
1A). Apoptosis was confirmed using DNA laddering (Figure 1C)
and annexin V binding (Figure 2) and was first apparent after only 6
h incubation (data not shown). The effect of 50 mM antagonist G on
apoptosis was inhibited by co-incubation with Z-Val-Ala-DL-Asp
fluormethylketone (ZVAD-fmk) (Figure 1C) from 36.5 ± 8.4% to
4.82 ± 1.38% (judged morphologically, n = 4), implicating the
activation of caspases in antagonist G-induced apoptosis.
Antagonist G-induced apoptosis was blocked by co-incubation
with the ROS scavenger N-acetyl cysteine (10 mM n-AC) and by
incubation under anoxic conditions (Figure 1B). This extends our
previous work and suggests that similar to JNK activation
(MacKinnon et al, 1999), antagonist G-induced apoptosis occurs
via an oxidant-dependent mechanism in SCLC cells.
Antagonist G-induced generation of intracellular ROS
in SCLC cells is cell type-specific
The finding that the apoptotic effect of antagonist G was abrogated
by n-AC and anoxia suggests that antagonist G requires the
Antagonist G induces AP-1 and generates ROS 943
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Figure 1 Effect of antagonist G on SCLC cell apoptosis. (A) SCLC cells H69 (l) and H510 (n) were washed and incubated in serum-free quiescent medium
with antagonist G or diluent (H2O) for 24 h at 37°C. Apoptosis was assessed morphologically using May–Grünwald–Giemsa stain as described in Methods. The
data is expressed as % increase in apoptosis and represents the mean ± SEM of four independent experiments performed in triplicate. Representative
photomicrographs (upper panel) of histologically stained H69 cells treated with diluent (left) or 30 mM antagonist G (right) for 24 h, showing the presence of
apoptotic bodies. (B) Antagonist G-induced apoptosis is inhibited by anoxia and n-acetyl cysteine. H69 cells cultured in SITA medium were quiesced overnight
in serum-free medium, washed and incubated (1 ´ 106 cells ml–1) in the absence (open bars) or presence (closed bars) of 25 mM antagonist G with or without 
10 mM n-acetyl cysteine (n-AC) for 24 h at 37°C. H69 cells were made anoxic by incubation in a MK3 anaerobic incubator (0% O2) at 37°C for 24 h. Apoptosis
was assessed morphologically using May–Grünwald–Giemsa stain as described in Methods. The results are expressed as % apoptotic cells and represent the
mean ± SEM of three–four separate experiments performed in duplicate. (C) Representative DNA ladder showing the effects of 25 mM antagonist G with or
without 100 mM ZVAD-fmk. *Statistically different from control; **statistically different from corresponding antagonist G control (P < 0.05 ANOVA)generation of ROS to induce apoptosis in SCLC cells. This was
formally examined by measuring intracellular ROS generation.
Cells were preloaded with the cell-permeable oxidant-sensitive
fluorescent dye dihydrorhodamine (DHR) and ROS generation
followed as an increase in fluorescence measured by flow cytom-
etry. H2O2 (200 mM) increased DHR fluorescence, causing a 5.1-
fold increase in H69 cells (from 1.8 ± 0.09 to 9.2 ± 3.2 mean
fluorescence units; n = 4, Figure 2B). Similar results were shown
in the H510 cell line (data not shown). At concentrations which
induce apoptosis, antagonist G produced a dose-dependent
increase in DHR fluorescence (Figure 2A) causing a 6.2-fold
increase with 100 mM antagonist G in SCLC cells. The finding
that this effect was evident within 15 min exposure to antagonist G
and well before morphological changes were apparent suggests
that this is a primary event involved in a pro-apoptotic pathway in
SCLC cells. This was emphasized by the finding that although the
antagonist G-induced increase in DHR fluorescence and apoptosis
was blocked by n-acetyl cysteine (Figure 2B and 2D), only the
apoptotic effect was inhibited by the caspase inhibitor ZVAD-fmk
(Figure 1C). ZVAD-fmk had no effect on antagonist-G induced
DHR fluorescence (data not shown). Antagonist G was not acting
as an oxygen donor itself as it had no effect on cytochrome c
oxidation in vitro (data not shown). However, antagonist G at
concentrations which increased ROS generation in the SCLC cell
lines had no effect on DHR fluorescence in CHO-K1 cells (Figure
2A). In addition, antagonist G did not induce apoptosis in CHO-
K1 cells (Figure 2C). These experiments indicate that the oxidant-
dependent apoptotic effect of antagonist G is not non-specific and
generally cytotoxic, but is cell type-specific.
Antagonist G depletes cellular glutathione
In keeping with a ROS-dependent mechanism, antagonist G 
(30 mM) increased peroxyl radical generation by 112% in H510
cells (Figure 3C) and depleted the levels of GSH by 38% in H510
cells. This reduction in cellular GSH levels was similar to that
observed with a maximal concentration of L-buthionine-(SR)-
sulfoximine (BSO, 0.1 mM), an inhibitor of the GSH synthesizing
enzyme glutamylcysteine synthetase (Figure 3A).
Ceramide is an important lipid second messenger which has
been implicated in the apoptotic response to a wide variety of
cellular stresses including oxidant stress (Haimovitz-Friedman et
944 AC MacKinnon et al
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Figure 2 (A) Antagonist G generates intracellular ROS in SCLC but not CHO-K1 cells. SCLC H69 (l) and CHO-K1 (n) cells were washed and incubated 
(106 cells ml–1) with 1 mM dihydrorhodamine (DHR) for 5 min at 37°C prior to the addition of antagonist G for a further 10 min at 37°C. Fluorescence was
measured by flow cytometry using an EPICS Profile II flow cytometer (Coulter Electronics, Luton, UK.). The data represent the mean ± SEM of four experiments
carried out in duplicate. (B) Effect of NAC on ROS generation. DHR-loaded H69 cells were preincubated with 5 mM n-AC for 20 min at 37°C. Cells were then
incubated in the absence or presence of 200 mM H2O2 or 50 mM antagonist G. Fluorescence was measured as in (C). The data are expressed as % increase in
DHR fluorescence and represent the mean ± SEM of at least three independent experiments carried out in duplicate. (C) Effect of antagonist G on H69 and
CHO-K1 cell apoptosis. H69 SCLC cells were treated as in Figure 1 and incubated with annexin V as described in Methods. CHO-K1 cells were treated 50 mM
antagonist G for 24 h in DMEM containing 0.1% fetal bovine serum. The percentage of annexin V-positive (apoptotic cells) was assessed by flow cytometry. The
data represent the mean ± SEM of at least three independent experiments carried out in duplicate. (D) Effect of n-AC on antagonist G-induced apoptosis. H69
cells were treated as in (B) in the presence or absence of 5 mM n-AC and/or 50 mM antagonist G. Apoptosis was assessed by annexin-V positivity and is
expressed as % apoptosis. The data represent the mean ± SEM of at least three independent experiments carried out in duplicate. *Statistically different from
control (P < 0.05 ANOVA)al, 1994; Verheij et al, 1996). The JNK cascade is one of the down-
stream signalling pathways activated by ceramide. We show that
antagonist G (50 mM) increases ceramide levels in SCLC cells
after 1 h and 24 h treatment (Figure 3B).
Antagonist G stimulates JNK and AP-1 activity
Figure 4A shows that antagonist G (25 mM) and H2O2 (200 mM)
stimulate JNK activity in H69 cells. The transcription factor AP-1
has been associated with apoptosis (Staal et al, 1990; Devary et al,
1991; Jarpe et al, 1998b) and its transcriptional activity is
increased by JNK (Staal et al, 1990; Devary et al, 1991). Figure 4B
shows that antagonist G (10 mM) increased AP-1 activation by 
61 ± 14% (n = 4) compared to an 84 ± 18% increase induced by
H2O2 (200 mM, n = 4, Figure 4B). The specificity was confirmed
by the inhibition of binding by unlabelled AP-1 but not NFkb
(Figure 4B). Thus, antagonist G stimulates JNK and AP-1 activa-
tion via a redox-sensitive mechanism in SCLC cells.
Antagonist G sensitizes SCLC cells to chemotherapy
Previous work has shown that modulation of the redox balance by
altering the levels of GSH changes the response of cells to cyto-
toxic drugs (Russo et al, 1984). Moreover, the levels of GSH have
been shown to increase in SCLC and NSCLC cells as they become
resistant to chemotherapy (Ikegaki et al, 1994). The ability of
antagonist G to increase ROS and deplete GSH suggests that
antagonist G may sensitize SCLC cells to chemotherapeutic
agents. We therefore examined whether antagonist G could poten-
tiate growth inhibition induced by the chemotherapeutic agent
etoposide.
Etoposide (0.3 mg ml–1), or antagonist G (5 mM) had no effect on
H69 SCLC cell growth individually, however, when added in
combination, H69 SCLC cell proliferation was inhibited by 24%
(Figure 5A). 50 mM antagonist G did inhibit growth by 59% and
this was potentiated to 79% inhibition in the presence of 
0.3 mg ml–1 etoposide. The effect of antagonist G on etoposide-
induced growth inhibition was more than additive and was syner-
gistic showing an augmentation of the maximum response to
etoposide rather than a change in affinity (Figure 2B). These data
show that antagonist G can sensitize SCLC cells to etoposide-
induced growth inhibition, and suggest an additional role for
antagonist G to be co-administered with standard chemotherapy in
the treatment of SCLC.
DISCUSSION
We demonstrate that altering the redox status of the cell toward a
more reduced environment modulates the pro-apoptotic effect of
antagonist G. This was demonstrated from observations that the
induction of apoptosis by antagonist G is inhibited under anoxic
conditions and that antagonist G directly increases the generation
of ROS within the cell. Antagonist G is not an oxygen donor itself
as it has no effect on isolated cytochrome c activity in vitro. We
suggest that the ability of antagonist G to stimulate intracellular
ROS is not a general cytotoxic effect as it is unable to increase
ROS generation and induce apoptosis in CHO-K1 cells and in
isolated human neutrophils (unpublished observations). Therefore,
it appears that antagonist G increases cellular ROS specifically in
SCLC cells. This, coupled with the finding that anoxia and N-
acetyl cysteine block the ability of antagonist G to induce apop-
tosis, suggests that this is an important part of its pro-apoptotic
mechanism of action, which occurs upstream of caspase activa-
tion.
The transcription factor AP-1 is regulated by JNK and its
transcriptional activity is increased by ROS in many cell types
(Staal et al, 1990; Devary, 1991; Buttke and Sandstrom, 1994;
Cossarizza et al, 1995; Lo and Cruz, 1995). Although increased
JNK and AP-1 activity is associated with cellular proliferation in
many cell types, in neuronal cells such as PC12 and in certain
models of stress-induced apoptosis, increased activity of JNK and
AP-1 are associated with apoptosis (Verheij et al, 1996; Jarpe 
Antagonist G induces AP-1 and generates ROS 945
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Figure 3 (A) Effect of antagonist G on GSH levels in SCLC cells. Quiescent cultures of H510 cells (5 ´ 106 cells ml–1) were incubated in serum-free medium in
the presence of 50 mM antagonist G (ant G) or 0.1 mM L-buthionine-[SR]-sulphoximine (BSO) for 24 h at 37°C. Total and oxidized GSH was measured from
cellular extracts as described in Methods. The data are expressed as nmole GSH ml–1 extract and represent the mean ± SEM of three–four independent
experiments performed in triplicate. (B) Ceramide production. SCLC H510 cells in SITA medium were incubated with 50 mM antagonist G for 1 h or 24 h at
37°C. Ceramide from extracted lipids was measured by the DAG kinase assay as described in Methods. The results are expressed as % increase above control
and represent the mean ± SEM of three experiments performed in triplicate. (C) Lipid peroxidation. SCLC H510 cells in serum-free media were incubated with
increasing concentrations of antagonist G for 24 h. Lipid peroxides were assayed as thiobarbituric acid reactive substances (TBARS) as described in Methods.
The data are expressed as % increase above control and represent mean ± SD of two independent experiments performed in triplicate. *Statistically different
from control (P < 0.05 ANOVA)et al, 1998b; Le-Niculescu et al, 1999). This study shows that
antagonist G increases AP-1 activity at concentrations which
induce apoptosis and activate JNK in SCLC cells, and gives
further evidence for the importance of ROS in the mediation of
antagonist G’s effects.
We show that antagonist G depletes the levels of the major
cellular antioxidant glutathione. There is evidence from other
systems that such a response can lead to a stimulation of the stress
pathway and programmed cell death. For example it has been
shown that glutathione directly inhibits sphingomyelinase (Liu
and Hannun, 1997), thereby reducing the levels of ceramide, an
important inducer of apoptosis in many cells (Haimowitz-
Friedman et al, 1994; Pena et al, 1997). In turn, ceramide stimu-
lates the electron transport chain of mitochondria, leaking free
946 AC MacKinnon et al
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three independent experiments. (B) H69 cells were incubated with etoposide (1–100 mg ml–1) in the absence (n n) or presence of 5 mM (l) or 50 mM (n)
antagonist G. Total cell number was determined at day 9. The data are expressed as cell number ml–1 and represent the mean ± SEM of three independent
experimentselectrons to generate superoxide anion (Zamzami et al, 1995)
which leads to a depletion of GSH and an increase in the genera-
tion of ROS (Quillet-May et al, 1997). In Jurkat T cells, the
cellular GSH level was suggested to be critical for ROS activation
of JNK in a pathway involving ras or other GTPases such as rac1
or cdc 42 as redox sensors (Lander et al, 1996). Therefore, it
appears that the level of GSH within the cell plays an important
role in modulating stress responses leading to apoptosis and cell
death.
Small cell lung cancer is characteristically resistant to oxidative
damage and lipid peroxidation (Galeotti et al, 1991). Patients with
lung cancer have increased levels of antioxidant GSH in the lungs,
which renders them more resistant to oxidant-or chemotherapy-
induced cell death (Russo et al, 1984; Melloni et al, 1996).
Moreover, modulation of GSH levels has been shown to change
the response of cells to cytotoxic drugs and ionizing radiation
(Carmichael et al, 1988). L-buthionine-SR-sulfoximine (BSO), an
inhibitor of g-glutamylcysteine synthetase, has undergone Phase I
clinical development to lower elevated GSH in patients with lung
cancer (Gallo et al, 1995), however, there is no compound
currently available which employs the dual function of increasing
ROS and depleting GSH with the potential to cause persistent acti-
vation of JNK and apoptosis. Here we show for the first time an
explicitly novel mechanism of action of antagonist G to induce
apoptosis through a redox-sensitive pathway. We also show that
antagonist G (at concentrations achieved clinically in the Phase I
studies (Clive et al, 1999) is able to synergistically sensitize SCLC
cells to etoposide at concentrations which were otherwise ineffec-
tive. This will have important implications for the future clinical
use of antagonist G as tumours progress from chemosensitive to
chemoresistant phenotypes. This suggests a role for antagonist G
not only as a sole treatment for SCLC but as an additional treat-
ment with chemotherapy. Antagonist G may therefore have a dual
beneficial role in SCLC and may also be of benefit in a variety of
other tumours by sensitizing them to subsequent chemotherapy.
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